BrainsGate

Company Overview

Snapshot

Founded in July 2000, BrainsGate operates with 11–50 employees. The company has raised $98.5M across 6 funding rounds from 11 investors. In December 2020, BrainsGate secured funding from BNP Paribas and Elron Ventures.

Business overview

BrainsGate is a medical device company focused on developing therapies for central nervous system diseases, particularly acute ischemic stroke. Its core technology involves electrical stimulation of the sphenopalatine ganglion to increase cerebral blood flow. The company's primary product is the Ischemic Stroke System (ISS), a miniature electrode implanted in the roof of the mouth through a minimally invasive procedure. BrainsGate serves the healthcare industry, targeting patients and providers within the Health Tech & Life Sciences sector.

Strategic signal

In December 2021, BrainsGate faced a negative FDA panel outcome, partly attributed to low U.S. enrollment in its clinical trials. This signals potential challenges in regulatory approval and market penetration within the critical U.S. healthcare landscape, indicating a need for strategic re-evaluation of its clinical trial approach and market entry strategy.

Company Intelligence Q&A

What is BrainsGate's primary focus?

BrainsGate focuses on developing minimally invasive treatments for central nervous system diseases, with a particular emphasis on acute ischemic stroke.

What is the company's core technology?

BrainsGate's core technology involves electrical stimulation of the sphenopalatine ganglion, a nerve center known to increase cerebral blood flow, utilized in its Ischemic Stroke System (ISS).

When did BrainsGate complete its ImPACT-1 pilot clinical trial?

BrainsGate completed its ImPACT-1 pilot clinical trial for acute ischemic stroke in 2008, which showed promising results.

What was the outcome of the FDA panel for BrainsGate in December 2021?

In December 2021, BrainsGate received a negative FDA panel outcome, which was partly driven by low U.S. enrollment in its clinical trials.

Which investors participated in BrainsGate's December 2020 funding round?

In December 2020, BrainsGate secured funding from BNP Paribas and Elron Ventures.